Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Durvalumab + Mogamulizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Durvalumab | Imfinzi | MEDI4736 | Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67 | Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov). |
Mogamulizumab | Poteligeo | KW-0761|Mogamulizumab-kpkc | Poteligeo (mogamulizumab-kpkc) is a monoclonal antibody that binds to and inhibits C-C chemokine receptor 4 (CCR4) signaling, which leads to inhibition of Tregs and enhancement of host antitumor immunity (PMID: 25496334). Poteligeo (mogamulizumab-kpkc) is FDA approved for adult patients with relapsed or refractory mycosis fungoides or Sezary syndrome (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | alveolar soft part sarcoma | not applicable | Durvalumab + Mogamulizumab | Case Reports/Case Series | Actionable | In a Phase I trial, a patient with alveolar soft part sarcoma achieved a partial response after 3.68 months with a response duration of 10.6 months following treatment with the combination of Poteligeo (mogamulizumab-kpkc) and Imfinzi (durvalumab) (PMID: 32586937; NCT02301130). | 32586937 |
Unknown unknown | Advanced Solid Tumor | no benefit | Durvalumab + Mogamulizumab | Phase I | Actionable | In a Phase I trial, the combination of Poteligeo (mogamulizumab-kpkc) and Imfinzi (durvalumab) demonstrated tolerability in patients with advanced solid tumors, but resulted in minimal efficacy, with an objective response rate of 5.3% (1/19, one partial response in a patient with alveolar soft part sarcoma), median progression-free survival of 1.9 months, and median overall survival of 8.9 months (PMID: 32586937; NCT02301130). | 32586937 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|